Eli Lilly and Company today announced changes in its executive committee.
Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after 28 years at Lilly. Norton currently is vice president, Global Quality for API Manufacturing, Product Research and Development.
Bart Peterson, senior vice president of Corporate Affairs and Communications, will leave Lilly March 31 to pursue personal business interests and expand his community volunteer commitments. Peterson, a former two-term mayor of Indianapolis, joined Lilly in 2009. A search currently is under way for his replacement.
“Fionnuala and Bart have been invaluable members of our executive committee as our business has gone through tremendous transformation during the last few years,” said David Ricks, Lilly president and CEO. “Fionnuala has worked diligently to ensure that we have maintained the highest quality standards across our worldwide operations, which is absolutely essential to our business. And, Bart’s leadership and political acumen have been vital to help us meet the significant challenges of an incredibly complex health care environment. His strong passion and vision for global health has been instrumental in making life better for people around the world.”
Ricks said Lilly is very fortunate to have Norton to step into Walsh’s role. “Johna lives Lilly’s values every day, has a strong commitment to our mission, sets the highest standards for her work and has demonstrated leadership in partnering across the business. She has a deep knowledge of our manufacturing and quality systems and has worked effectively with regulators globally.”
Source: Eli Lilly and Company
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
